Moore Capital Management LP Purchases Shares of 237,892 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Moore Capital Management LP bought a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 237,892 shares of the company's stock, valued at approximately $1,106,000. Moore Capital Management LP owned approximately 0.06% of GoodRx as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of GDRX. Barclays PLC lifted its holdings in shares of GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company's stock worth $973,000 after buying an additional 130,219 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of GoodRx in the third quarter worth $5,675,000. JPMorgan Chase & Co. lifted its holdings in shares of GoodRx by 358.7% in the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company's stock worth $169,000 after buying an additional 18,997 shares in the last quarter. Sugar Maple Asset Management LLC purchased a new position in shares of GoodRx in the fourth quarter worth $122,000. Finally, Gagnon Securities LLC lifted its holdings in shares of GoodRx by 9.9% in the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock worth $325,000 after buying an additional 6,266 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Trading Down 1.2%

GDRX stock traded down $0.05 during mid-day trading on Friday, reaching $3.96. 1,286,385 shares of the stock traded hands, compared to its average volume of 1,390,980. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx Holdings, Inc. has a one year low of $3.68 and a one year high of $9.26. The stock has a market capitalization of $1.52 billion, a PE ratio of -132.00, a PEG ratio of 2.46 and a beta of 1.24. The business has a 50-day moving average price of $4.45 and a two-hundred day moving average price of $4.66.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million for the quarter, compared to analysts' expectations of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.08 earnings per share. Equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on GDRX shares. Wells Fargo & Company reduced their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. UBS Group reduced their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. The Goldman Sachs Group reduced their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, Truist Financial reduced their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GoodRx has an average rating of "Moderate Buy" and an average target price of $6.55.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.